Boundless Bio IncNASDAQ:BOLD
- LAST PRICE3.6350
- TODAY'S CHANGE (%)0.0550 (1.5363%)
- Bid / Lots3.6200/ 5
- Ask / Lots3.6400/ 7
- Open / Previous Close3.5600 / 3.5800
- Day Range
- 52 Week Range
- Volume24,493
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BOLD |
|---|---|---|
| 09:32 ET | 462 | 3.56 |
| 09:42 ET | 100 | 3.605 |
| 10:33 ET | 500 | 3.6 |
| 10:36 ET | 324 | 3.605 |
| 10:38 ET | 600 | 3.6199 |
| 10:45 ET | 500 | 3.6101 |
| 10:47 ET | 200 | 3.6407 |
| 11:12 ET | 100 | 3.66 |
| 11:14 ET | 100 | 3.6551 |
| 11:21 ET | 100 | 3.65 |
| 11:41 ET | 108 | 3.635 |
| 11:43 ET | 200 | 3.62 |
| 11:48 ET | 2311 | 3.6 |
| 12:01 ET | 652 | 3.62 |
| 12:14 ET | 2300 | 3.68 |
| 12:19 ET | 200 | 3.67 |
| 12:30 ET | 798 | 3.67 |
| 12:35 ET | 100 | 3.62 |
| 12:42 ET | 100 | 3.63 |
| 12:46 ET | 100 | 3.63 |
| 12:55 ET | 1759 | 3.61 |
| 01:02 ET | 1685 | 3.61 |
| 01:11 ET | 100 | 3.64 |
| 01:26 ET | 100 | 3.6 |
| 01:27 ET | 1273 | 3.63 |
| 01:36 ET | 204 | 3.635 |
| 01:38 ET | 100 | 3.62 |
| 01:51 ET | 500 | 3.612078 |
| 02:09 ET | 100 | 3.67 |
| 02:12 ET | 100 | 3.66 |
| 02:16 ET | 400 | 3.655 |
| 02:18 ET | 391 | 3.69 |
| 02:21 ET | 581 | 3.7 |
| 02:25 ET | 1317 | 3.64 |
| 02:32 ET | 100 | 3.635 |
| 02:50 ET | 100 | 3.64 |
| 02:52 ET | 100 | 3.64 |
| 02:54 ET | 190 | 3.6314 |
| 02:56 ET | 100 | 3.635 |
Nov 7, 2024
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference, from 7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
Oct 14, 2024
DJ Boundless Bio CFO Jami Rubin Steps Down for Personal Reasons, from 8:18AM ET on Monday Oct 14, 2024 by Dow Jones
8:18AM ET on Monday Oct 14, 2024 by Dow JonesBoundless Bio Announces Departure of Chief Financial Officer, from 8:00AM ET on Monday Oct 14, 2024 by Dow Jones
8:00AM ET on Monday Oct 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Boundless Bio Inc | 79.7M | -1.4x | --- |
ESSA Pharma Inc | 79.5M | -3.0x | --- |
Regencell Bioscience Holdings Ltd | 79.1M | -19.6x | --- |
Sellas Life Sciences Group Inc | 80.4M | -1.5x | --- |
Citius Pharmaceuticals Inc | 81.2M | -1.9x | --- |
ALX Oncology Holdings Inc | 78.0M | -0.5x | --- |
Company Information
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
Contact Information
- Headquarters
- 9880 Campus Point Drive, Suite 120SAN DIEGO, CA, United States 92121
- Phone
- 858-766-9912
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jonathan Lim
- President, Chief Executive Officer, Director
- Zachary Hornby
- Principal Financial Officer, Principal Accounting Officer, Treasurer
- David Hinkle
- Chief Scientific Officer
- Christian Hassig
- Chief Business Officer
- Neil Abdollahian
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.60 |
Book Value | $5.42 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
